Cambridge Epigenetix Stock

cambridge-epigenetix.comHealthcareFounded: 2012Funding to Date: $57.08MM

Cambridge Epigenetix (CEGX) is a life sciences tools and analytics company that has created a technology platform delivering step changes in both the type of information that can be generated from DNA and the cost at which it is gathered.

Register for Details

For more details on financing and valuation for Cambridge Epigenetix, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Cambridge Epigenetix.

Register Today

Team

Management Team

Joanne Mason Ph.D
Vice President, Biomarker Discovery
Vitali Proutski Ph.D
Vice President, Informatics
Bobby Yerramilli-Rao Ph.D
Co-Founder & Chairman
Shankar Balasubramanian
Co-Founder & Chairman of Scientific Advisory Board
Hayden Jeffreys
Chief Operating Officer
Deborah Tonge
Director of Finance
Jason Mellad Ph.D
Chief Executive Officer & Board Member

Board Members

Jason Mellad Ph.D
Shankar Balasubramanian
Tom Hulme
GV
Bobby Yerramilli-Rao Ph.D
Somasundaram Subramaniam
New Science Ventures
Alice Newcombe-Ellis
Ahren Innovation Capital
Martin Murphy Ph.D
Syncona
Roelof Botha
Sequoia Capital
Timothy Rink MD

Other companies like Cambridge Epigenetix in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 

News

VC firm GV (née Google Ventures) has made another investment in Europe -- its seventh -- leading a $21 million Series B round for epigenetic sequencing tech company and Cambridge University spin-out, Cambridge Epigenetix.